Adaptive immunity in HBV infection

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages S71-S83

  Bertoletti, Antonio ^a,b   Ferrari, Carlo ^c  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c Azienda Ospedaliero Universitaria di Parma   (Italy)

Author keywords

Antiviral immunity; B lymphocytes; Immunodominance; T cell exhaustion; T lymphocytes

Indexed keywords

NEUTRALIZING ANTIBODY; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL SPECIFICITY; CHRONIC HEPATITIS B; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; HEPATITIS B, CHRONIC; IMMUNOLOGY; T LYMPHOCYTE; VIROLOGY;

ADAPTIVE IMMUNITY; ANTIVIRAL AGENTS; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; T-LYMPHOCYTES;

EID: 85010908324     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.01.026     Document Type: Review

References (148)

1. [1] Oldstone, M.B.A., Whitton, J.L., Fields virology. 4 ed., 2001, Lippincott Williams & Wilkins, Philadelphia.
2. [2] Rock, K.L., Goldberg, A.L., Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17 (1999), 739–779.
3. [3] Roche, P.A., Furuta, K., The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 15 (2015), 203–216.
4. [4] Haniffa, M., Shin, A., Bigley, V., McGovern, N., Teo, P., See, P., et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 37 (2012), 60–73.
5. [5] Yewdell, J.W., Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25 (2006), 533–543.
6. [6] Chisari, F.V., Ferrari, C., Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13 (1995), 29–60.
7. [7] Bertoletti, A., Ferrari, C., Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61 (2012), 1754–1764.
8. [8] Schuch, A., Hoh, A., Thimme, R., The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection. Front Immunol, 5, 2014, 258.
9. [9] Gish, R.G., Given, B.D., Lai, C.-L., Locarnini, S.A., Lau, J.Y.N., Lewis, D.L., et al. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res 121 (2015), 47–58.
10. [10] Gerlich, W.H., Medical virology of hepatitis B: how it began and where we are now. Virol J, 10, 2013, 239.
11. [11] Hoofnagle, J.H., Gerety, R.J., Barker, L.F., Antibody to hepatitis-B-virus core in man. Lancet 2 (1973), 869–873.
12. [12] Farci, P., Diaz, G., Chen, Z., Govindarajan, S., Tice, A., Agulto, L., et al. B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A 107 (2010), 8766–8771.
13. [13] Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1 (2012), e00049–e00059.
14. [14] Ni, Y., Lempp, F.A., Mehrle, S., Nkongolo, S., Kaufman, C., Fälth, M., et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146 (2014), 1070–1083.
15. [15] Urban, S., Bartenschlager, R., Kubitz, R., Zoulim, F., Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147 (2014), 48–64.
16. [16] Jaoudé, G.A., Sureau, C., Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 79 (2005), 10460–10466.
17. [17] Glebe, D., Aliakbari, M., Krass, P., Knoop, E.V., Valerius, K.P., Gerlich, W.H., Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 77 (2003), 9511–9521.
18. [18] Ryu, C.J., Gripon, P., Park, H.R., Park, S.S., Kim, Y.K., Guguen-Guillouzo, C., et al. In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen. J Med Virol 52 (1997), 226–233.
19. [19] Le Seyec, J., Chouteau, P., Cannie, I., Guguen-Guillouzo, C., Gripon, P., Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol 72 (1998), 5573–5578.
20. [20] Samuel, D., Muller, R., Alexander, G., Fassati, L., Ducot, B., Benhamou, J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993), 1842–1847.
21. [21] Werner, J.M., Abdalla, A., Gara, N., Ghany, M.G., Rehermann, B., The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 145 (2013), 1026–1034.
22. [22] Rybczynska, J., Campbell, K., Kamili, S., Locarnini, S., Krawczynski, K., Walker, C.M., CD4+ T cells are not required for suppression of hepatitis B virus replication in the liver of vaccinated chimpanzees. J Infect Dis, 2015, 10.1093/infdis/jiv348.
23. [23] Chen, C.-L., Yang, J.-Y., Lin, S.-F., Sun, C.-A., Bai, C.-H., You, S.-L., et al. Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol 63 (2015), 354–363.
24. [24] Petersen, J., Dandri, M., Mier, W., Lütgehetmann, M., Volz, T., Weizsäcker von, F., et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26 (2008), 335–341.
25. [25] Oliviero, B., Cerino, A., Varchetta, S., Paudice, E., Pai, S., Ludovisi, S., et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 55 (2011), 53–60.
26. [26] Xu, X., Shang, Q., Chen, X., Nie, W., Zou, Z., Huang, A., et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Molec Immunol 12 (2015), 309–316.
27. [27] Vanwolleghem, T., Hou, J., van Oord, G., Andeweg, A.C., Osterhaus, A.D.M.E., Pas, S.D., et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 62 (2015), 87–100.
28. [28] Dusheiko, G.M., Hoofnagle, J.H., Cooksley, W.G., James, S.P., Jones, E.A., Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest 71 (1983), 1104–1113.
29. [29] Barnaba, V., Valesini, G., Levrero, M., Zaccari, C., Van Dyke, A., Falco, M., et al. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 60 (1985), 259–266.
30. [30] Böcher, W.O., Herzog-Hauff, S., Herr, W., Heermann, K., Gerken, G., Meyer Zum Büschenfelde, K.H., et al. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 105 (1996), 52–58.
31. [31] Böcher, W.O., Galun, E., Marcus, H., Daudi, N., Terkieltaub, D., Shouval, D., et al. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse. Hepatology 31 (2000), 480–487.
32. [32] Xu, L., Yin, W., Sun, R., Wei, H., Tian, Z., Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc Natl Acad Sci U S A 110 (2013), 16993–16998.
33. [33] Milich, D.R., McLachlan, A., Thornton, G.B., Hughes, J.L., Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329 (1987), 547–549.
34. [34] Li, Y., Ma, S., Tang, L., Li, Y., Wang, W., Huang, X., et al. Circulating chemokine (C-X-C Motif) receptor 5 +CD4 +T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 58 (2013), 1277–1286.
35. [35] Madaliński, K., Bragiel, I., HBsAg immune complexes in the course of infection with hepatitis B virus. Clin Exp Immunol 36 (1979), 371–378.
36. [36] Gerlich, W.H., The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis 44 (2007), 1170–1172.
37. [37] Kunkel, E.J., Butcher, E.C., Plasma-cell homing. Nat Rev Immunol 3 (2003), 822–829.
38. [38] Mohamadkhani, A., Naderi, E., Sotoudeh, M., Katoonizadeh, A., Montazeri, G., Poustchi, H., Clinical feature of intrahepatic B-lymphocytes in chronic hepatitis B. Int J Inflam 2014 (2014), 896864–896865.
39. [39] Das, A., Ellis, G., Pallant, C., Lopes, A.R., Khanna, P., Peppa, D., et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189 (2012), 3925–3935.
40. [40] Araki, K., Nagashima, H., Tsuji, T., Detection and characterization of circulating immune complexes during acute exacerbation of chronic viral hepatitis. Clin Exp Immunol 47 (1982), 520–526.
41. [41] Maruyama, T., Schödel, F., Iino, S., Koike, K., Yasuda, K., Peterson, D., et al. Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Gastroenterology 106 (1994), 1006–1015.
42. [42] Zhang, T.-Y., Yuan, Q., Zhao, J.-H., Zhang, Y.-L., Yuan, L.-Z., Lan, Y., et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2015, 10.1136/gutjnl-2014-308964 [Epub ahead of print].
43. [43] Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
44. [44] Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
45. [45] Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V., The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996), 1104–1108.
46. [46] Penna, A., Artini, M., Cavalli, A., Levrero, M., Bertoletti, A., Pilli, M., et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98 (1996), 1185–1194.
47. [47] Kefalakes, H., Jochum, C., Hilgard, G., Kahraman, A., Bohrer, A.M., Hindy El, N., et al. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable. J Hepatol 63 (2015), 13–19.
48. [48] Dervite, I., Hober, D., Morel, P., Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 (2001), 68–69.
49. [49] Evens, A.M., Jovanovic, B.D., Su, Y.-C., Raisch, D.W., Ganger, D., Belknap, S.M., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22 (2011), 1170–1180.
50. [50] Moriyama, T., Guilhot, S., Klopchin, K., Moss, B., Pinkert, C.A., Palmiter, R.D., et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248 (1990), 361–364.
51. [51] Maini, M.K., Boni, C., Lee, C.K., Larrubia, J.R., Reignat, S., Ogg, G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000), 1269–1280.
52. [52] Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K.A., Purcell, R.H., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 (2003), 68–76.
53. [53] Guidotti, L.G., Ishikawa, T., Hobbs, M.V., Matzke, B., Schreiber, R., Chisari, F.V., Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4 (1996), 25–36.
54. [54] Ando, K., Moriyama, T., Guidotti, L.G., Wirth, S., Schreiber, R.D., Schlicht, H.J., et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 178 (1993), 1541–1554.
55. [55] Kakimi, K., Lane, T.E., Wieland, S., Asensio, V.C., Campbell, I.L., Chisari, F.V., et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 194 (2001), 1755–1766.
56. [56] Yang, P.L., Althage, A., Chung, J., Maier, H., Wieland, S., Isogawa, M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 107 (2010), 798–802.
57. [57] Ferrari, C., Penna, A., Bertoletti, A., Valli, A., Antoni, A.D., Giuberti, T., et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145 (1990), 3442–3449.
58. [58] Maini, M.K., Boni, C., Ogg, G.S., King, A.S., Reignat, S., Lee, C.K., et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117 (1999), 1386–1396.
59. [59] Webster, G.J., Reignat, S., Maini, M.K., Whalley, S.A., Ogg, G.S., King, A., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32 (2000), 1117–1124.
60. [60] Boettler, T., Panther, E., Bengsch, B., Nazarova, N., Spangenberg, H.C., Blum, H.E., et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80 (2006), 3532–3540.
61. [61] Sandalova, E., Laccabue, D., Boni, C., Tan, A.T., Fink, K., Ooi, E.E., et al. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog, 6, 2010, e1001051.
62. [62] Zhang, Z., Zhang, J.-Y., Wherry, E.J., Jin, B., Xu, B., Zou, Z.-S., et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134 (2008), 1938–1949 1949.e1–e3.
63. [63] Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137 (2009), 1289–1300.
64. [64] Sandalova, E., Laccabue, D., Boni, C., Watanabe, T., Tan, A., Zong, H.Z., et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143 (2012), 78–87 e3.
65. [65] Pallett, L.J., Gill, U.S., Quaglia, A., Sinclair, L.V., Jover-Cobos, M., Schurich, A., et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med 21 (2015), 591–600.
66. [66] Franzese, O., Kennedy, P.T.F., Gehring, A.J., Gotto, J., Williams, R., Maini, M.K., et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 79 (2005), 3322–3328.
67. [67] Zerbini, A., Pilli, M., Boni, C., Fisicaro, P., Penna, A., Di Vincenzo, P., et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134 (2008), 1470–1481.
68. [68] Penna, A., Chisari, F.V., Bertoletti, A., Missale, G., Fowler, P., Giuberti, T., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174 (1991), 1565–1570.
69. [69] Bertoletti, A., Ferrari, C., Fiaccadori, F., Penna, A., Margolskee, R., Schlicht, H.J., et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 88 (1991), 10445–10449.
70. [70] Webster, G.J.M., Reignat, S., Brown, D., Ogg, G.S., Jones, L., Seneviratne, S.L., et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78 (2004), 5707–5719.
71. [71] Bengsch, B., Martin, B., Thimme, R., Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61 (2014), 1212–1219.
72. [72] Kurktschiev, P.D., Raziorrouh, B., Schraut, W., Backmund, M., Wachtler, M., Wendtner, C.M., et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med, 54, 2014, 167.
73. [73] Loggi, E., Bihl, F.K., Cursaro, C., Granieri, C., Galli, S., Brodosi, L., et al. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One, 8, 2013, e65327.
74. [74] Hong, M., Sandalova, E., Low, D., Gehring, A.J., Fieni, S., Amadei, B., et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun, 6, 2015, 6588.
75. [75] Bertoletti, A., Hong, M., Age-dependent immune events during HBV infection from birth to adulthood: an alternative interpretation. Front Immunol, 5, 2014, 441.
76. [76] Jung, M.C., Spengler, U., Schraut, W., Hoffmann, R., Zachoval, R., Eisenburg, J., et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 13 (1991), 310–317.
77. [77] Sobao, Y., Sugi, K., Tomiyama, H., Saito, S., Fujiyama, S., Morimoto, M., et al. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A∗2402, the most common HLA class I allele in East Asia. J Hepatol 34 (2001), 922–929.
78. [78] Nayersina, R., Fowler, P., Guilhot, S., Missale, G., Cerny, A., Schlicht, H.J., et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150 (1993), 4659–4671.
79. [79] Abbott, W.G.H., Tsai, P., Leung, E., Trevarton, A., Ofanoa, M., Hornell, J., et al. Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. J Virol 84 (2010), 621–629.
80. [80] Rehermann, B., Fowler, P., Sidney, J., Person, J., Redeker, A., Brown, M., et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181 (1995), 1047–1058.
81. [81] Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Viganò, M., Schivazappa, S., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143 (2012), 963–969.
82. [82] Chisari, F.V., Cytotoxic T cells and viral hepatitis. J Clin Invest 99 (1997), 1472–1477, 10.1172/JCI119308.
83. [83] Ferrari, C., Bertoletti, A., Penna, A., Cavalli, A., Valli, A., Missale, G., et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88 (1991), 214–222.
84. [84] Kakimi, K., Isogawa, M., Chung, J., Sette, A., Chisari, F.V., Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 76 (2002), 8609–8620.
85. [85] Rivino, L., Tan, A.T., Chia, A., Kumaran, E.A.P., Grotenbreg, G.M., Macary, P.A., et al. Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity. J Immunol 191 (2013), 4010–4019.
86. [86] Bertoni, R., Sidney, J., Fowler, P., Chesnut, R.W., Chisari, F.V., Sette, A., Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 100 (1997), 503–513.
87. [87] Tan, A.T., Loggi, E., Boni, C., Chia, A., Gehring, A.J., Sastry, K.S.R., et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 82 (2008), 10986–10997.
88. [88] Tsai, S.L., Chen, M.H., Yeh, C.T., Chu, C.M., Lin, A.N., Chiou, F.H., et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest 97 (1996), 577–584.
89. [89] Chen, X., Wang, W., Wang, S., Meng, G., Zhang, M., Ni, B., et al. An immunodominant HLA-A∗1101-restricted CD8+ T-cell response targeting hepatitis B surface antigen in chronic hepatitis B patients. J Gen Virol 94 (2013), 2717–2723.
90. [90] Tan, A.T., Sodsai, P., Chia, A., Moreau, E., Chng, M.H.Y., Tham, C.Y.L., et al. Immunoprevalence and immunodominance of HLA-Cw∗0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region. J Virol 88 (2014), 1332–1341.
91. [91] Hirsch, R.C., Lavine, J.E., Chang, L.J., Varmus, H.E., Ganem, D., Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344 (1990), 552–555.
92. [92] Gehring, A.J., Sun, D., Kennedy, P.T.F., Nolte-’t Hoen, E., Lim, S.G., Wasser, S., et al. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 81 (2007), 2940–2949.
93. [93] Maini, M.K., Reignat, S., Boni, C., Ogg, G.S., King, A.S., Malacarne, F., et al. T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. Eur J Immunol 30 (2000), 3067–3078.
94. [94] Park, J.-J., Wong, D.K., Wahed, A.S., Lee, W.M., Feld, J.J., Terrault, N., et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology, 2015, 10.1053/j.gastro.2015.11.050.
95. [95] Rehermann, B., Pasquinelli, C., Mosier, S.M., Chisari, F.V., Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 96 (1995), 1527–1534.
96. [96] Bertoletti, A., Costanzo, A., Chisari, F.V., Levrero, M., Artini, M., Sette, A., et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 180 (1994), 933–943.
97. [97] Bertoletti, A., Sette, A., Chisari, F.V., Penna, A., Levrero, M., De Carli, M., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369 (1994), 407–410.
98. [98] Kefalakes, H., Budeus, B., Walker, A., Jochum, C., Hilgard, G., Heinold, A., et al. Adaptation of the hepatitis B virus core protein to CD8(+) T-cell selection pressure. Hepatology 62 (2015), 47–56.
99. [99] Desmond, C.P., Gaudieri, S., James, I.R., Pfafferott, K., Chopra, A., Lau, G.K., et al. Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 86 (2012), 1181–1192.
100. [100] Liu, H.-G., Fan, Z.-P., Chen, W.-W., Yang, H.-Y., Liu, Q.-F., Zhang, H., et al. A mutant HBs antigen (HBsAg)183–191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients. Clin Exp Immunol 151 (2008), 441–447.
101. [101] Hoh, A., Heeg, M., Ni, Y., Schuch, A., Binder, B., Hennecke, N., et al. Hepatitis B virus-infected HepG2hNTCP cells serve as a novel immunological tool to analyze the antiviral efficacy of CD8+ T cells in vitro. J Virol 89 (2015), 7433–7438.
102. [102] Sijts, A.J., Ruppert, T., Rehermann, B., Schmidt, M., Koszinowski, U., Kloetzel, P.M., Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 191 (2000), 503–514.
103. [103] Lau, G.K.K., Suri, D., Liang, R., Rigopoulou, E.I., Thomas, M.G., Mullerova, I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122 (2002), 614–624.
104. [104] Ilan, Y., Nagler, A., Adler, R., Naparstek, E., Or, R., Slavin, S., et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18 (1993), 246–252.
105. [105] Lindemann, M., Koldehoff, M., Fiedler, M., Schumann, A., Ottinger, H.D., Heinemann, F.M., et al. Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. Bone Marrow Transplant, 2015, 10.1038/bmt.2015.253.
106. [106] Balkow, S., Kersten, A., Tran, T.T., Stehle, T., Grosse, P., Museteanu, C., et al. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 75 (2001), 8781–8791.
107. [107] Guidotti, L.G., Inverso, D., Sironi, L., Di Lucia, P., Fioravanti, J., Ganzer, L., et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 161 (2015), 486–500.
108. [108] Iannacone, M., Hepatic effector CD8(+) T-cell dynamics. Cell Mol Immunol, 2014, 10.1038/cmi.2014.78.
109. [109] Billerbeck, E., Kang, Y.H., Walker, L., Lockstone, H., Grafmueller, S., Fleming, V., et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 107 (2010), 3006–3011.
110. [110] Knolle, P.A., Thimme, R., Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146 (2014), 1193–1207.
111. [111] Guidotti, L.G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., Chisari, F.V., Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999), 825–829.
112. [112] Phillips, S., Chokshi, S., Riva, A., Evans, A., Williams, R., Naoumov, N.V., CD8+ T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 184 (2009), 287–295.
113. [113] Xia, Y., Stadler, D., Lucifora, J., Reisinger, F., Webb, D., Hösel, M., et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology, 2015, 10.1053/j.gastro.2015.09.026.
114. [114] Fiedler, M., Rodicker, F., Salucci, V., Lu, M., Aurisicchio, L., Dahmen, U., et al. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-) and IFN-: IFN- but Not IFN- reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol 78 (2004), 10111–10121.
115. [115] Jacquard, A.C., Nassal, M., Pichoud, C., Ren, S., Schultz, U., Guerret, S., et al. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 48 (2004), 2683–2692.
116. [116] Guidotti, L.G., McClary, H., Loudis, J.M., Chisari, F.V., Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med 191 (2000), 1247–1252.
117. [117] Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
118. [118] Wolf, M.J., Seleznik, G.M., Zeller, N., Heikenwalder, M., The unexpected role of lymphotoxin β receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. Oncogene 29 (2010), 5006–5018.
119. [119] Haybaeck, J., Zeller, N., Wolf, M.J., Weber, A., Wagner, U., Kurrer, M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16 (2009), 295–308.
120. [120] Koeberlein, B., zur Hausen, A., Bektas, N., Zentgraf, H., Chin, R., Nguyen, L.T., et al. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res 148 (2010), 51–59.
121. [121] Fletcher, S.P., Chin, D.J., Ji, Y., Iniguez, A.L., Taillon, B., Swinney, D.C., et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 56 (2012), 820–830.
122. [122] Lopes, A.R., Kellam, P., Das, A., Dunn, C., Kwan, A., Turner, J., et al. Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. J Clin Invest 118 (2008), 1835–1845.
123. [123] Wherry, E.J., Ha, S.-J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
124. [124] Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81 (2007), 4215–4225.
125. [125] Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138 (2010), 682–684.
126. [126] Raziorrouh, B., Schraut, W., Gerlach, T., Nowack, D., Grüner, N.H., Ulsenheimer, A., et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52 (2010), 1934–1947.
127. [127] Schurich, A., Khanna, P., Lopes, A.R., Han, K.J., Peppa, D., Micco, L., et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53 (2011), 1494–1503.
128. [128] Peppa, D., Gill, U.S., Reynolds, G., Easom, N.J.W., Pallett, L.J., Schurich, A., et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210 (2013), 99–114.
129. [129] Boni, C., Lampertico, P., Talamona, L., Giuberti, T., Invernizzi, F., Barili, V., et al. Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology, 62, 2015, 10.1002/hep.28155.
130. [130] Isogawa, M., Chung, J., Murata, Y., Kakimi, K., Chisari, F.V., CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog, 9, 2013, e1003490.
131. [131] Schurich, A., Pallett, L.J., Lubowiecki, M., Singh, H.D., Gill, U.S., Kennedy, P.T., et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog, 9, 2013, e1003208.
132. [132] Richer, M.J., Nolz, J.C., Harty, J.T., Pathogen-specific inflammatory milieux tune the antigen sensitivity of CD8. Immunity 38 (2013), 140–152.
133. [133] Chisari, F.V., Nakamura, M., Milich, D.R., Han, K., Molden, D., Leroux-Roels, G.G., Production of two distinct and independent hepatic immunoregulatory molecules by the perfused rat liver. Hepatology 5 (1985), 735–743.
134. [134] Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5 (2005), 641–654.
135. [135] Das, A., Hoare, M., Davies, N., Lopes, A.R., Dunn, C., Kennedy, P.T.F., et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205 (2008), 2111–2124.
136. [136] Mann, D.A., Marra, F., Fibrogenic signalling in hepatic stellate cells. J Hepatol 52 (2010), 949–950.
137. [137] Kennedy, P.T.F., Sandalova, E., Jo, J., Gill, U., Ushiro-Lumb, I., Tan, A.T., et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143 (2012), 637–645.
138. [138] Wursthorn, K., Jung, M., Riva, A., Goodman, Z.D., Lopez, P., Bao, W., et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52 (2010), 1611–1620.
139. [139] Bertoletti, A., Kennedy, P.T., The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 12 (2015), 258–263.
140. [140] Zoulim, F., Mason, W.S., Reasons to consider earlier treatment of chronic HBV infections. Gut 61 (2012), 333–336.
141. [141] Fletcher, S.P., Chin, D.J., Gruenbaum, L., Bitter, H., Rasmussen, E., Ravindran, P., et al. Intrahepatic transcriptional signature associated with response to interferon-α treatment in the woodchuck model of chronic hepatitis B. PLoS Pathog 11 (2015), e1005103–e1005131.
142. [142] Kosinska, A.D., Zhang, E., Johrden, L., Liu, J., Seiz, P.L., Zhang, X., et al. Combination of DNA prime – adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9, 2013, e1003391.
143. [143] Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog, 10, 2014, e1003856.
144. [144] Sitia, G., Aiolfi, R., Di Lucia, P., Mainetti, M., Fiocchi, A., Mingozzi, F., et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 109 (2012), E2165–E2172.
145. [145] Rehermann, B., Lau, D., Hoofnagle, J.H., Chisari, F.V., Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97 (1996), 1655–1665.
146. [146] Sitia, G., Iannacone, M., Muller, S., Bianchi, M.E., Guidotti, L.G., Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leuk Biol 81 (2006), 100–107.
147. [147] Bertoletti, A., Rivino, L., Hepatitis B: future curative strategies. Curr Opin Infect Dis 27 (2014), 528–534.
148. [148] Maini, M.K., Gehring, A.J., The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 64 (2016), S60–S70.